Public health guidance on HIV, hepatitis B and C testing in the EU/EEA - An integrated approach

Sep 15, 2026

This ECDC scientific advice provides integrated public health guidance for HIV and hepatitis B and C testing across the EU/EEA. It frames why integrated testing is needed, specifies eligibility for testing, and outlines where testing should occur. The guidance describes the rationale, objective, and scope, and sets out recommendations aimed at appropriate target audiences to support consistent, evidence-informed testing strategies and improved prevention and care outcomes.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages111

Reading Time4 h 40 min

AccessFree to download

Executive summary

Why integrated testing?

Who to test?

Where to test?

1 Introduction

1.1 Rationale

1.2 Integrated guidance on HBV, HCV and HIV testing

1.3 Objective and scope

1.4 Target audience

SCIENTIFIC ADVICE Public health guidance on HIV, hepatitis B and C tes~~ting ~~in the EU/EEA An integr~~a~~ted approach [www.ecdc.europa.eu](www.ecdc.europa.eu) ECDC SCIENTIFIC ADVICE Public health guidance on HIV, hepatitis Band C testing in the EU/EEA An integrated approach This guidance was commissioned by the European Centre for Disease Prevention and Control (ECDC), coordinated by Andrew J Amato-Gauci and Lara Tavoschi with the support of Helena de Carvalho Gomes from ECDC and the ECDC Library, and produced by a consortium led by CHIP/Region H, Rigshospitalet, University of Copenhagen (CHIP/Region H) with Public Health England (PHE), St Stephen’s AIDS Trust (SSAT) and the European Aids Treatment Group (EATG), framework contract ECDC/2016/035 . Authors Ann Sullivan, SSAT, Ayla van Ahee, Pallas Health Research and Consultancy (Pallas (HRC), Caroline Rae, SSAT, Dorthe Raben, CHIP/Region H, Rigshospitalet, Lauren Combs, CHIP/Region H, Lauren Mason, Pallas HRC, Misha Hoekstra, independent consultant, Sara Croxford, Public Health England (PHE), Sarika Desai, PHE, Stine Finne Jakobsen, CHIP/Region H, Valerie Delpech, PHE, Yazdan Yazdanpanah, French National Institute of Health and Medical Research (INSERM) Acknowledgements Agathe Leon, Infectious Disease Department, Hospital Clinic of Barcelona, Spain Andrew Winter, International Union Against Sexually Transmitted Infections (IUSTI), National Health Service (NHS) Greater Glasgow and Clyde, United Kingdom Bartosz Szetela, Wroclaw Medical University, Poland Dagmar Hedrich, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Portugal Daniel Simões, EATG/Grupo de Ativistas em Tratamentos, Portugal Deniz Gokengin, IUSTI, Turkey Eve Robinson, Ireland Irena Klavs, National Institute of Public Health (NIJZ), Slovenia Irene Veldhuijzen, National Institute for Public Health and the Environment (RIVM), Netherlands Jan van Bergen, Soa Aids Nederland, Netherlands Jason Farrell, Correlation Network, Choices Support Center, Netherlands Jens Lundgren, CHIP/Region H, Denmark Jessika Deblonde, Sciensano, Belgium Jordi Casabona, Center of Epidemiological Studies on HIV and STI in Catalonia (CEEISCAT), Spain Justyna Kowalska, Medical University of Warsaw, Poland Kristi Rüütel, National Institute for Health Development, Estonia Maria Axelsson, Public Health Agency of Sweden, Sweden Maria Elena Tosti, Istituto Superiore di Sanità, Italy Matthew Hickman, University of Bristol, United Kingdom Masoud Dara, World Health Organization (WHO) Regional Office for Europe, Denmark Michael Ninburg, World Hepatitis Alliance, United Kingdom Mika Salminen, National Institute for Health and Welfare, Finland Mojca Maticic, University Medical Centre Ljubljana, Slovenia Nikos Dedes, EATG/Positive Voice, Greece Peter Vickerman, University of Bristol, United Kingdom Philippa Easterbrook, WHO, Switzerland Raj Patel, IUSTI/NHS England, United Kingdom Ruta Kaupe, DIA+LOGS, Latvia Slim Fourati, European Association for the Study of the Liver (EASL), France Tatiana Reic, European Liver Patients’ Association (ELPA), Croatia The authors would also like to acknowledge the contributions to the project from Erika Duffell, Teymur Noori, Anastasia Pharris and Lina Nerlander at ECDC, their colleagues at CHIP/Region H and Public Health England and everyone who submitted case studies describing best-practice interventions. Suggested citation: European Centre for Disease Prevention and Control. Public health guidance on HIV, hepatitis Band C testing in the EU/EEA – An integrated approach. Stockholm: ECDC; 2018. Stockholm, November 2018 PDF Print ISBN 978-92-9498-286-5 ISBN 978-92-9498-294-0 DOI 10.2900/79127 DOI 10.2900/489464 Catalogue number TQ-06-18-328-EN-N Catalogue number TQ-06-18-328-EN-C © European Centre for Disease Prevention and Control, 2018 Cover picture: © iStock Reproduction is authorised, provided the source is acknowledged. For any u

FAQs

Why does the guidance promote integrated HIV, HBV and HCV testing?

It explains that integrated testing supports a coordinated public health approach, improving consistency and enabling more effective identification of people who need further services.

Who should be tested according to the guidance?

The executive summary outlines who to test, defining the target groups for HIV and hepatitis B and C testing within the EU/EEA context.

Where should testing be provided?

The document provides section guidance on where to test, describing appropriate testing settings across the EU/EEA.

Sep 15, 2026

Upload by Taylor Morgan